1. Substance and claimed effects

The substance is structured physical exercise — predominantly aerobic (walking, jogging, cycling) and resistance training — prescribed as an intervention for unipolar depressive symptoms ranging from subclinical to major depressive disorder (MDD). The defining claim is that exercise reduces depressive symptom severity to a degree comparable with first-line pharmacotherapy and psychotherapy, with replicated effects across populations and modalities Noetel et al. 2024, Singh et al. 2023. Adjacent consequences relevant to scoring include broad mortality reduction, sleep architecture improvement, cognitive performance (especially executive function and hippocampal-dependent memory), daily energy / vitality, body composition and cardiovascular fitness with downstream visible effects, and prevention of incident depression in non-depressed populations Pearce et al. 2022, Schuch et al. 2018, Erickson et al. 2011. The substance is non-prescription, low-cost, and effectively dose-titratable; the central practical question is therapeutic dose, not access.

2. Evidence by addressing question

Mechanism

Several biological pathways converge plausibly. Acute and chronic aerobic exercise raises peripheral brain-derived neurotrophic factor (BDNF), a neurotrophin implicated in hippocampal neurogenesis and synaptic plasticity; the meta-analytic effect on serum BDNF is large after single bouts (g=0.46) and meaningful with repeated training, with attenuated magnitude in females Szuhany et al. 2015. Chronic aerobic training in older adults increases anterior hippocampal volume by ~2% over one year, reversing typical age-related atrophy and tracking improved memory performance — a hippocampal-volume increment of clinical interest because the hippocampus is structurally smaller in MDD Erickson et al. 2011. Additional plausible mechanisms include normalization of HPA-axis hyperactivity, reduction in chronic low-grade inflammation (CRP, IL-6, TNF-α), improved vagal tone and heart-rate variability, increased monoamine availability acutely, and downstream effects via improved sleep, body composition, and self-efficacy Mikkelsen et al. 2017. None of these mechanisms is decisively isolated as the cause of mood improvement, but the redundancy of the mechanistic case makes "no plausible pathway" untenable.

Evidence

The most recent and largest synthesis is a 2024 BMJ network meta-analysis of 218 RCTs covering 14,170 participants with clinical depression diagnoses. Compared with usual care, walking/jogging produced a standardised mean difference (SMD) of -0.62, yoga -0.55, strength training -0.49, mixed aerobic exercise -0.42, and tai chi/qigong -0.42. Dance produced the largest point estimate (-0.96) but on far fewer trials. Effects were larger at higher intensities and held in adults of both sexes and across ages, including with comorbid conditions Noetel et al. 2024. A 2023 BJSM umbrella review of 97 prior meta-analyses (over 1,000 RCTs, ~128,000 participants) reported a pooled median SMD of -0.43 for depression, with higher-intensity activity yielding larger effects and shorter (~12-week) programs outperforming longer ones Singh et al. 2023. A 2023 BJSM meta-analysis restricted to clinical depression diagnoses reported still larger pooled effects (overall SMD ~-0.95; strength training alone ~-1.04; combined aerobic + strength ~-0.46) Heissel et al. 2023. A meta-analysis adjusted for publication bias reported an overall SMD of ~-1.11 against non-active controls in MDD, attenuating but remaining significant after trim-and-fill Schuch et al. 2016. Resistance training has its own dedicated meta-analysis (33 RCTs, 1,877 participants): pooled SMD -0.66, independent of strength gains, total dose, or baseline depression status Gordon et al. 2018.

Head-to-head comparisons with first-line treatments are limited in number but consistent in direction. In the SMILE trial (n=156 MDD adults over 50), 16 weeks of supervised aerobic exercise (three 45-minute sessions weekly at 70–85% max heart rate) matched sertraline's remission rate; the exercise arm showed slightly faster initial response with sertraline and equivalent endpoint outcomes Blumenthal et al. 1999. Ten-month follow-up found that participants who continued exercising had lower relapse than the medication arm Babyak et al. 2000. SMILE-II (n=202) confirmed equivalence of supervised exercise, home-based exercise, and sertraline against placebo over 16 weeks, all three active arms producing similar remission rates above placebo Blumenthal et al. 2007. In Cochrane's 2013 pooled analysis (39 trials, 2,326 participants), exercise outperformed control at SMD -0.62; head-to-head, exercise was statistically indistinguishable from antidepressants (SMD -0.11) and from psychological therapy (SMD -0.03); when limited to the highest-quality trials, the exercise-vs-control effect shrank to a small SMD of ~-0.18 Cooney et al. 2013. The 2017 BMJ Open update applying trial sequential analysis concluded that the evidence remained inconclusive given small, high-risk-of-bias trials, with the most rigorous estimates compatible with a clinically trivial effect Krogh et al. 2017.

For context: in the largest network meta-analysis of antidepressants (522 trials, ~117,000 patients), the pooled SMD of antidepressants vs placebo for acute MDD treatment was ~-0.30 (odds ratio 1.66 for response) — i.e., exercise's pooled effect size in the 2024 BMJ review and in publication-bias-adjusted meta-analyses meets or exceeds typical drug-vs-placebo effects, though drug trials are uniformly blinded whereas exercise trials cannot be Cipriani et al. 2018. Pooled effect sizes for evidence-based psychotherapy vs control hover around SMD -0.7 against waitlist and ~-0.3 to -0.5 against active controls Cuijpers et al. 2023.

Exercise is also studied as augmentation. In TREAD (n=126 SSRI non-remitters), 12 weeks of supervised aerobic exercise at the "public health dose" (16 kcal/kg/week ≈ 150 min/week brisk walking) produced 28.3% remission vs 15.5% in a low-dose comparison arm (NNT ≈ 7.8) Trivedi et al. 2011. In treatment-resistant patients on stable adequate pharmacotherapy, adding 30–45 minutes of moderate exercise 5×/week produced 21% remission and 26% response vs 0% / 0% in pharmacotherapy alone at 12 weeks Mota-Pereira et al. 2011. SEEDS, in late-life depression, found that adding aerobic exercise to sertraline outperformed sertraline alone on affective symptoms, particularly depressed mood and psychomotor retardation, with the progressive-aerobic group benefiting most Belvederi Murri et al. 2015.

Prevention is a separate evidence stream. A 2018 prospective-cohort meta-analysis (49 studies, ~267,000 participants, median 7.4-year follow-up) found that meeting physical activity recommendations was associated with a 17% reduction in incident depression, consistent across age, sex, and continent Schuch et al. 2018. A 2022 JAMA Psychiatry dose-response meta-analysis (15 cohorts, 2+ million person-years) found a curvilinear inverse relationship: half the WHO-recommended dose (~8.8 mMET-h/week, equivalent to ~75 min/week brisk walking) was associated with an 18% lower risk of depression; meeting the full guideline dose conferred a 25% reduction; further increases yielded marginal returns Pearce et al. 2022.

Protocol

Across trials, the dose range with replicated efficacy is roughly 150 minutes/week moderate-intensity or 75 minutes/week vigorous-intensity aerobic exercise — the WHO/ACSM standard WHO 2020. The DOSE study (n=80 mild-to-moderate MDD) directly tested this: a "public health dose" of 17.5 kcal/kg/week reduced Hamilton Depression Rating Scale scores by 47%, more than double the 30% reduction in a low-dose arm of 7 kcal/kg/week; frequency (3× vs 5× per week) did not matter at matched weekly volume Dunn et al. 2005. Heissel's meta-regression and the 2024 BMJ network meta-analysis both find greater effects at higher intensities; Singh's umbrella review concurs Singh et al. 2023, Noetel et al. 2024, Heissel et al. 2023. Resistance training shows an antidepressant effect across a broad range of doses, with effect size independent of total volume in Gordon's meta-regression Gordon et al. 2018. The practical clinical protocol — supervised when possible, 3–5×/week, 30–60 minutes per session, progressive in intensity, ≥8 weeks duration, ideally outdoor or social — appears to be the consensus operating prescription across trials.

Contraindications

For aerobic and resistance exercise at the moderate-vigorous intensities studied, true medical contraindications are narrow: unstable cardiac disease, acute decompensated heart failure, severe uncontrolled hypertension, recent cardiac event without medical clearance, and active eating-disorder pathology where exercise functions as a compensatory behaviour. Pregnancy is not a contraindication to moderate exercise but warrants tailoring. The dominant practical "contraindication" is severe melancholic or psychotic depression where motivation collapse and psychomotor retardation make the intervention infeasible without intensive support — not a safety contraindication but a feasibility one. Stubbs's meta-analysis of dropout in 40 exercise-depression RCTs found a pooled dropout of 18.1% in the exercise arms (vs higher in control), with no excess attrition relative to typical psychotherapy or pharmacotherapy trials — meaning the feasibility ceiling is real but not catastrophic Stubbs et al. 2016.

Misconceptions

Three patterns dominate the gap between literature and lay belief. First: "exercise improves mood" gets shrunken in popular framing to a feel-good wellness adjunct, obscuring the clinical magnitude — exercise's effect size on diagnosed MDD is in the same ballpark as antidepressants and psychotherapy, not a soft supplement Noetel et al. 2024, Cipriani et al. 2018. Second: the public-health dose is widely under-prescribed in clinical settings — clinicians who recommend exercise rarely specify intensity, frequency, or duration, while the trials with the largest effects use supervised, progressive, intensity-titrated protocols Heissel et al. 2023. Third: aerobic and resistance training are both effective; the lay default of "cardio is for depression" ignores Gordon's meta-analysis showing resistance training's SMD -0.66, independent of strength gain Gordon et al. 2018.

Audience

Effects generalize broadly. The 2024 BMJ network analysis found that men and women, younger and older adults, and people with chronic comorbidities all benefited; women may benefit slightly more from strength training and men from yoga, but interaction effects are small Noetel et al. 2024. Older adults are well-studied (SMILE, SEEDS, Belvederi Murri's work) and respond similarly, with the practical advantage of fewer pharmacotherapy options due to polypharmacy and adverse-event risk; aerobic exercise in late-life depression also confers cognitive and disability benefits beyond mood Blumenthal et al. 1999, Belvederi Murri et al. 2015. Adolescents and perinatal populations are studied in smaller bodies of evidence with consistent direction. The population where exercise has the weakest signal is severe melancholic or psychotic depression — not because it doesn't work, but because feasibility collapses Stubbs et al. 2016.

Alternatives

The competing first-line treatments are antidepressant medication (SSRIs, SNRIs) and structured psychotherapy (cognitive behavioural therapy, behavioural activation, interpersonal therapy). The most rigorous head-to-head trials show statistical equivalence at 12–16 weeks across exercise, sertraline, and CBT Blumenthal et al. 1999, Blumenthal et al. 2007, Hallgren et al. 2015. Exercise's distinguishing advantages are non-prescription access, broad consequence profile (cardiovascular, metabolic, cognitive, sleep, body composition), absent pharmacological side-effect burden, and lower long-term relapse when continued Babyak et al. 2000. Its disadvantages are activation cost (requires effort the depressed reader has least of), the need for adequate dose and intensity, and the absence of a delivery system as scalable as a prescription.

Failure modes

The trial-real-world gap is the main failure mode. Trials use supervised, dose-monitored, social-context protocols with adherence support; self-prescribed exercise in a depressed person without scaffolding typically fails on initiation rather than on efficacy. Heissel's meta-regression finds that shorter (<12-week) supervised interventions outperform longer ones, suggesting that the supervised structure may matter more than the duration Heissel et al. 2023. Dropout in exercise arms of trials is ~18%; in unsupported self-initiated exercise, real-world dropout is higher and unmeasured Stubbs et al. 2016. The most common pattern of failure: too low intensity, too sporadic frequency, no progression, no accountability structure. Exercise that doesn't reach a target intensity may not engage the BDNF and HPA-axis pathways most plausibly responsible for the antidepressant effect.

Practicalities

Cost is near-zero for walking, jogging, or bodyweight resistance training; modest for gym membership ($300–$1,200/year); moderate for personal training or supervised group programs ($1,000–$5,000/year). Time burden is the dominant cost: 150 minutes/week is ~22 minutes/day. Equipment requirements range from running shoes to a small home setup. Insurance coverage for exercise prescription is rare in the US but expanding under value-based care contracts; the UK NHS has commissioned exercise referral schemes under NICE guidance NICE 2022. The largest practical friction in depressed populations is initiation: the activation-energy cost is highest in the population that needs the intervention most.

Stakes

Untreated depression carries substantial direct mortality (suicide risk, all-cause mortality elevation), occupational and relational impairment, and downstream physical health degradation. Sedentary behaviour, independent of depression, is a major contributor to cardiovascular and metabolic mortality. The compound case for not addressing low physical activity in a depressed adult is therefore double — losses to both mental health and cardiovascular trajectory. The cohort evidence shows clear dose-response between physical activity and depression risk in the general population: people meeting WHO guidelines have ~25% lower depression risk; even half-dose activity confers ~18% reduction Pearce et al. 2022.

Payoff

Onset of antidepressant effect in trials emerges between weeks 2 and 4 with meaningful symptom reductions visible by week 8 and full response by weeks 12–16 in most successful protocols Dunn et al. 2005, Blumenthal et al. 2007. Sleep onset, energy, and subjective vitality often shift within the first 2–4 weeks of consistent training; mood lift typically lags slightly. Long-term: continued exercise after acute response confers protection against relapse — the SMILE 10-month follow-up found that exercise-arm participants who kept exercising had a relapse rate of 8% vs 38% in those who stopped Babyak et al. 2000. Beyond mood, the consequence chain includes cardiovascular fitness gains, sleep quality, cognitive performance (executive function, hippocampal-dependent memory), reduced inflammation, improved body composition, and ~20–30% mortality reductions seen in physical-activity cohort literature at maintained dose Erickson et al. 2011, Mikkelsen et al. 2017.

History

Recommendations for movement as a treatment for melancholy predate modern psychiatry — found in Hippocratic texts, Galenic medicine, and 19th-century moral-treatment-era asylum practice (gardening, walking, agricultural labour as therapy). Systematic RCT investigation began in the 1980s; Blumenthal's SMILE trials in the 1990s established the head-to-head equivalence finding that has anchored the modern evidence base Blumenthal et al. 1999. Major guideline bodies have incorporated exercise as a first-line or adjunctive recommendation: NICE recommends group-based exercise for less-severe depression as one of several first-line options NICE 2022; APA recommends exercise for adults with MDD particularly for those preferring alternatives to medication or psychotherapy APA 2019.

3. The credibility range

The optimist case

The 2024 BMJ network meta-analysis is one of the largest and most methodologically rigorous syntheses of any depression intervention ever conducted — 218 RCTs, 14,170 patients with diagnosed depression — and it reports moderate-to-large pooled effects across multiple modalities, with the largest effects at higher intensities Noetel et al. 2024. Three independent contemporary meta-analyses (Heissel 2023, Schuch 2016, Singh 2023) converge on similar magnitudes after attempting to correct for publication bias and trial heterogeneity. Head-to-head trials of meaningful size (SMILE, SMILE-II, REGASSA, SEEDS, TREAD) show statistical equivalence with sertraline and CBT — and superior maintenance at long-term follow-up Babyak et al. 2000. The mechanistic case is multi-pathway and biologically plausible: BDNF, hippocampal neurogenesis, HPA-axis normalization, inflammation, monoamines, sleep, self-efficacy. Cohort epidemiology in the general population confirms a dose-response prevention effect — physical activity is causally protective against incident depression across millions of person-years Pearce et al. 2022, Schuch et al. 2018. Resistance training has its own dedicated meta-analytic base with effects roughly equivalent to aerobic, broadening the modality menu Gordon et al. 2018. The intervention has no pharmacological side effects, confers wide-spectrum non-mood benefits, and is accessible at near-zero cost. The optimist's strong claim: exercise is a first-line depression treatment whose effect size is competitive with — and sometimes superior to — antidepressants and structured psychotherapy, with a far better adverse-event profile and substantial collateral benefits.

The skeptic case

Exercise trials cannot be double-blinded. Participants randomized to exercise know they are exercising; placebo-controlled comparisons are limited to active-comparator designs (stretching, attention controls), all of which leak expectancy. The Cochrane 2013 review found that the SMD shrank from -0.62 to ~-0.18 when restricted to the highest-quality trials with adequate allocation concealment, blinded outcome assessment, and intention-to-treat analysis — a small effect, possibly clinically trivial Cooney et al. 2013. The 2017 BMJ Open trial sequential analysis concluded the question was not settled given the predominance of small, high-risk-of-bias trials and stated that the most rigorous estimates were compatible with no clinically meaningful effect Krogh et al. 2017. The publication-bias-adjusted estimate from Schuch 2016 (~-0.66 after trim-and-fill) is consistent with substantial small-study and reporting bias inflating the literature Schuch et al. 2016. Head-to-head equivalence with antidepressants is based on small trials with limited power to detect non-inferiority. Adherence in real-world dissemination is far lower than in supervised trials; the trial-to-clinic translation gap may erode much of the effect. Cohort epidemiology cannot resolve reverse causation — depressed people exercise less because they are depressed, not the other way around. The skeptic's strong claim: the true effect of self-administered exercise on diagnosed MDD is small once trial bias is properly controlled, and most of the apparent advantage comes from expectancy and supervision effects that don't transfer to a depressed person told to "go for a walk."

The author's call

The evidence base is large, the mechanisms are plausible and multiple, the modality and dose are flexible, and the head-to-head equivalence with antidepressants — even at the conservative end of the effect-size range — is more than sufficient to make exercise a first-line option. The blinding problem is real but cannot be solved (this is true of psychotherapy too, which is uncontroversially first-line), and the cohort-level prevention effect is independent of any blinding issue in treatment trials. Most of the high-quality-trial attenuation observed in Cochrane 2013 reflects strict methodology penalising the older trial set; the 2024 BMJ network analysis with much higher-quality trial inclusion still finds moderate-to-large effects. The strongest practical caveat is dose: under-dosed, unsupervised, sporadic exercise is the modal real-world delivery, and that version likely does not achieve the effect sizes seen in trials. The honest framing is that exercise is a well-evidenced treatment whose effect ceiling depends sharply on whether the reader actually reaches the studied dose — meeting it likely yields antidepressant-class benefit; falling well short likely doesn't. Evidence: 4. Controversy: 2 — disagreement exists at the methodological margin (true effect size after rigorous bias control), but no serious camp now claims "exercise doesn't help depression."

4. Stakeholder and incentive map

• Pro-exercise. Sports medicine and exercise physiology research communities; integrative-health and lifestyle-medicine advocates; public-health bodies (WHO, ACSM, USPSTF endorsements for physical activity broadly); clinicians frustrated with medication side-effect burden and partial-response rates; patients seeking non-pharmacological options. Generally low commercial incentive — no industry profits from a person exercising more — though gyms, fitness apps, and wearables have a tangential financial stake.
• Skeptic / counter-incentive. Methodologists rightly concerned about blinding and bias inflation in unblindable trials; some psychiatry voices wary of overselling exercise to patients with severe melancholic depression who cannot initiate; pharmaceutical industry has indirect interest in framing antidepressants as the first-line standard. Some clinicians worry that an "exercise prescription" without supervision functions as a brush-off for the patient.
• Cultural. Wellness influencers and self-improvement communities oversell exercise as a near-panacea, eroding clinical credibility through hyperbole. The "just go for a walk" trope from non-depressed people to depressed people is a community-level invalidation that has soured many depressed patients on exercise advice altogether.
• Guideline bodies. NICE (UK), APA (US), and CANMAT (Canada) all recommend exercise as a treatment option, though typically positioned as adjunct or alternative rather than first-line equal to pharmacotherapy/psychotherapy — guideline conservatism reflects the blinding issue and trial-quality concerns more than the effect-size question.

5. Population variability

• Sex. Effects generalize across sexes; modality preference may differ (some evidence of larger BDNF response in men, larger strength-training benefit in women's MDD), but pooled effect sizes are similar Szuhany et al. 2015, Noetel et al. 2024.
• Age. Late-life depression responds well (SMILE, SEEDS), with added cognitive and physical-function benefits. Adolescents and young adults respond with smaller bodies of evidence but in the same direction. Mid-life adults (the modal MDD population) are well-represented in the trial base.
• Severity. Strongest evidence is in mild-to-moderate depression. Severe MDD with melancholic or psychotic features: feasibility limits effect; supervised programs and combination with pharmacotherapy are required.
• Treatment-resistant depression. Augmentation evidence (TREAD, Mota-Pereira) supports adding exercise to ongoing pharmacotherapy in non-remitters, with meaningful remission rates achievable.
• Comorbidities. Cardiovascular disease, type 2 diabetes, obesity — exercise carries additional benefit and is generally safe with standard pre-participation screening. Eating-disorder history: caution; exercise can function as a compensatory behaviour.
• Baseline activity. Largest absolute mood gains are in sedentary populations; well-trained athletes plateau on the curve, though resistance training adds modest benefit even at high baseline aerobic fitness Gordon et al. 2018.

6. Knowledge gaps

True double-blind comparisons of exercise to placebo are impossible by design — this ceiling on study quality won't change. The question of how much of the trial effect transfers to unsupervised self-prescription remains poorly quantified; pragmatic trials in primary-care prescription settings (REGASSA-type) are needed at larger scale Hallgren et al. 2015. The minimum effective dose for clinical depression — versus the WHO general-population recommendation — is not precisely characterized; Dunn's dose study remains the cleanest direct comparison and is small Dunn et al. 2005. The relative efficacy of modalities (aerobic vs resistance vs yoga vs mixed) in head-to-head terms is still indirect, derived from network analyses rather than direct comparisons. Mechanism — whether BDNF, neurogenesis, HPA-axis, inflammation, or self-efficacy is the dominant pathway — remains unresolved; it may be that the multiplicity of effects is itself the mechanism. Whether exercise added to optimized pharmacotherapy adds meaningfully to remission rates in non-resistant patients, beyond TREAD's narrow non-remitter population, is under-studied. Whether exercise can replace maintenance pharmacotherapy after acute response — a critical practical question given Babyak's finding of low relapse with continued exercise — has not been adequately tested.

7. Per-dimension evidence summary

• mood. Primary outcome in the entire trial literature; pooled SMDs of -0.4 to -0.95 across major meta-analyses, head-to-head equivalence with SSRIs and CBT, cohort-level prevention with dose-response. Score driver.
• energy. Improvement in subjective vitality and fatigue is a near-universal trial finding within 2–4 weeks; cardiovascular adaptation lifts daily energy floor over 8–12 weeks; resistance training reduces fatigue independent of strength gains Gordon et al. 2018.
• focus. Aerobic exercise improves executive function and processing speed; hippocampal volume gains track memory improvements; chronic training improves attention and working memory across age ranges Erickson et al. 2011, Mikkelsen et al. 2017.
• sleep. Aerobic and resistance training improve sleep onset latency, sleep efficiency, and slow-wave sleep; effects emerge over weeks of consistent training. Bidirectional benefit with mood improvement.
• longevity. Physical activity is one of the most robust mortality predictors in cohort epidemiology — meeting WHO guidelines confers ~20–30% all-cause mortality reductions; cardiovascular disease, type 2 diabetes, several cancers, dementia all show consistent inverse associations.
• health_short_term. Cardiovascular fitness, blood pressure, insulin sensitivity, body composition, musculoskeletal capacity — all improve over 8–16 weeks at studied doses. Felt impact on daily functioning is substantial.
• beauty_direct. Skin perfusion / post-exercise flush is real but transient. Not a primary effect within days–weeks.
• beauty_cumulative. Body composition change, postural improvement, cardiovascular skin tone, and reduced skin glycation via improved metabolic health all contribute to a meaningful long-term aesthetic shift over months to years.
• cost_burden. Walking and bodyweight work are free; gym membership and equipment trivial-to-minor; supervised programs minor-to-moderate. The dominant cost is time, not money.
• effort_burden. 150 min/week moderate intensity is ~22 min/day; sustained over months is substantial willpower in a depressed person whose baseline activation is impaired. Initiation is the hardest cost.
• evidence. Hundreds of RCTs across decades, multiple high-quality meta-analyses, cohort epidemiology in millions, multi-pathway mechanism, guideline endorsement — 4. Capped below 5 by the unsolvable blinding problem.
• controversy. No serious camp denies efficacy. Methodological disagreement on true effect size after bias correction; clinical disagreement on positioning (first-line equal vs adjunct). 2.

Scoping. The brief named "aerobic and resistance exercise as interventions for depressive symptoms, including dose ranges and effect sizes relative to pharmacological and psychotherapeutic treatments." The article covers all four — aerobic and resistance get explicit modality treatment in protocol and evidence; the 150 min/week dose and the DOSE-trial dose-response anchor the protocol section; the SMILE / SMILE-II / Cochrane equivalence with sertraline and CBT carry the comparison. No narrowing relative to brief.

Holistic scoring vs framing tension. The framing of this entry is depression-treatment-specific, but per spec §1a the meta scores are holistic against the substance — exercise's longevity, energy, focus, sleep, and short-term health effects are real and non-zero whether or not the article centres on them. Those dimensions get paragraph-level coverage in mechanism and payoff so the article tracks the meta. A future "Exercise" entry (general movement / fitness rather than depression-specific) would re-cover this ground at greater depth; this entry stays in the mental-health lane.

• Beauty (direct) at 0. Initially considered 1 for the post-exercise flush, but the dimension targets days-to-weeks topical effects and the flush is hourly. The cleaner call is 0; cumulative beauty captures the real long-run aesthetic shift.
• Mood at 4, not 5. SMILE/SMILE-II head-to-head equivalence with sertraline and the 2024 BMJ network analysis arguably support 5 ("transformative; on the level of an effective psychiatric intervention"), but the Cochrane 2013 high-quality-trial attenuation to SMD -0.18 and the Krogh 2017 trial-sequential analysis create enough uncertainty at the rigorous end that 5 felt over-claimed. 4 fits the honest middle of the credibility range.
• Evidence capped at 4. Exercise trials are unblindable by design; that's a hard ceiling on study-quality grading, independent of the size of the literature. Five would require placebo-comparable blinding, which can't exist here.
• Controversy at 2. No camp denies efficacy; the live disagreement is about effect-size magnitude after methodological correction. That's margin-level pushback, not foundational disagreement.
• Effort burden at 3, not 4. 22 minutes a day doesn't meet the "an hour+ daily" anchor for 4, even though depression makes the willpower cost feel larger than the time cost would suggest. Captured the activation-cost honestly in the pitch and in failure-modes rather than inflating the score.

Category. Placed in mental rather than exercise because the entry's framing and most useful entry point is for someone thinking about depression treatment. A reader browsing Movement & Exercise will be looking for general fitness coverage; this entry is the mental-health-specific lens on exercise.

Contraindications. Included cardiac-condition, uncontrolled-hypertension, and eating-disorder-history. Eating-disorder history is the non-obvious one — included because exercise can quietly function as a compensatory behaviour and worsen the underlying problem; flagged in the warning callout. Pregnancy intentionally not included — moderate exercise during pregnancy is recommended, not contraindicated, with standard tailoring; mild adjustment, not exclusion.

Future-link candidates (unwritten or potentially un-IDed). The related field assumes entries for general exercise, depression (the condition), psychotherapy, and ssri-antidepressants; some or all may not yet exist. Editor to wire these once they land. The out-of-scope section also references sleep / circadian alignment and morning sunlight, which likely live in sleep and light categories.

Separate-entry candidates surfaced during writing.

• Behavioural activation — distinct from generic CBT and has its own evidence base in depression; would be a natural sibling.
• Treatment-resistant depression: augmentation strategies — the TREAD / Mota-Pereira / SEEDS augmentation findings touched here belong in a broader treatment-resistance entry.
• Late-life depression — SMILE and SEEDS specifically address the older-adult cohort with a different cost-benefit calculus than mid-life MDD.

Excluded by design. Depression itself as a diagnostic entity, the choice between SSRI / SNRI / atypical antidepressants, specific psychotherapy modality comparisons, and the programming detail of general exercise (Z2 vs threshold, periodisation, etc.) — all out of scope for the depression-specific lens. Pointed at in out-of-scope rather than expanded here.